Trial Profile
A muticenter study of Adalimumab in patients with Behcet's Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2017
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Behcet's syndrome
- Focus Therapeutic Use
- 17 Jun 2017 Short and long-term follow-up results (n=74) presented at the 18th Annual Congress of the European League Against Rheumatism
- 22 Jul 2016 New trial record
- 11 Jun 2016 Results presented at the 17th Annual Congress of the European League Against Rheumatism